Search the Newsreel

Veracyte Debuts Prosigna Breast Test in the U.S.

Veracyte Inc. has launched its Prosigna Breast Risk of Recurrence (ROR) test in the U.S. This genomic assay helps patients with early-stage hormone-receptor positive breast cancer determine their 10-year risk of distant recurrence, guiding personalized treatment decisions, including whether chemotherapy will be beneficial. The …

Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT

Bank of America Corp DE increased its stake in Veracyte, Inc. by 14.7% in the first quarter, holding 1.45 million shares valued at $46.7 million. Other institutional investors also raised their positions, and analysts maintain a "Moderate Buy" rating with an average target price …

How Investors May Respond To Veracyte (VCYT) Raising 2026 Revenue Guidance After Returning To Profit

Veracyte (VCYT) has raised its full-year 2026 revenue guidance to $590-$596 million and reported a return to profit in Q2 2026, with net income of $25.49 million. This improved outlook, driven by increasing test adoption, strengthens the company's investment narrative, although risks around reimbursement …

A Look at Veracyte Inc (VCYT) After 3.7% Decline -- GF Value $38

Veracyte Inc (VCYT) shares recently declined by 3.7%, trading at $44.68, which is 15.6% above its GF Value™ estimate of $38.64, indicating it is "modestly overvalued." Despite a strong GF Score™ of 82/100, driven by high growth and financial strength, the company has a …

Amundi Sells 116,588 Shares of Veracyte, Inc. $VCYT

Amundi significantly reduced its stake in Veracyte, Inc. by selling 116,588 shares, a 90.6% decrease, though other institutional investors increased their holdings. Veracyte surpassed Q1 earnings and revenue estimates, reporting $0.54 EPS and $150.32 million in revenue, leading analysts to maintain a "Moderate Buy" …

Veracyte at canaccord growth conference: growth balanced with margins

Veracyte (VCYT) outlined a strategy for growth balanced with disciplined spending at Canaccord Genuity’s 46th Annual Growth Conference. The company raised its full-year 2024 revenue guidance to $600 million after strong Q2 results, achieving over 29% adjusted EBITDA margin and over $40 million in …

Veracyte, Inc. $VCYT Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC reduced its stake in Veracyte, Inc. (NASDAQ:VCYT) by 31% in the first quarter, selling 84,255 shares but still retaining 187,368 shares valued at approximately $6 million. Despite this sale, analyst sentiment remains largely positive with a "Moderate Buy" rating and …

Royal Bank of Canada Grows Stock Holdings in Veracyte, Inc. $VCYT

Royal Bank of Canada increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 66.4% in the first quarter, acquiring an additional 228,720 shares, bringing its total to 573,096 shares valued at approximately $18.46 million. This move is part of a broader trend of institutional investors …

Veracyte Inc (VCYT) Earnings Forecast: Future EPS & Revenue Growth Estimates

Veracyte Inc (VCYT) has an earnings forecast score of 8.46, ranking 126th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $48.00, with a consensus "Buy" rating based on 13 analysts. The company's expected revenue for the next …

Results: Veracyte, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Veracyte, Inc. exceeded analyst expectations for its quarterly results, with revenues hitting US$150m and statutory EPS at US$0.31, 19% above forecasts. Following these positive results, analysts have slightly increased their earnings per share outlook for 2026, though the consensus revenue estimates remain largely unchanged. …

Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potential

VERACYTE INC : PIPER SANDLER CUTS TARGET PRICE TO $54.00 FROM $66.00

Piper Sandler has reduced its target price for VERACYTE INC (VCYT.O) to $54.00 from $66.00. This report was issued by Reuters on August 4, 2026. The article advises readers that its content reflects the author's opinion and should not be used as the sole …

VCYT Maintained by Stephens & Co. -- Price Target Lowered to $55

Stephens & Co. has maintained an Overweight rating for Veracyte (VCYT) but lowered its price target from $68.00 to $55.00. The stock is currently considered 16.3% overvalued by GuruFocus, trading at $44.84 against a GF Value™ of $38.56, despite a strong GF Score™ of …

Medicare Coverage Granted for Veracyte’s Test for Muscle-Invasive Bladder Cancer

Veracyte Inc.'s TrueMRD Monitoring Test has received Medicare coverage for recurrence monitoring in patients with muscle-invasive bladder cancer (MIBC) following definitive treatment. This marks Veracyte's first molecular residual disease (MRD) offering and the only commercially available whole-genome MRD test, significantly expanding its reach into …

Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests

Veracyte (VCYT) shares dropped 18.2% despite the company raising its full-year 2026 revenue guidance to US$590 million to US$596 million, up from a previous range, following strong Q2 results of US$150.32 million revenue and US$25.49 million net income. This improved outlook is attributed to …

Canaccord cuts Veracyte stock price target to $50 on revenue outlook

Canaccord has lowered its price target for Veracyte (NASDAQ: VCYT) to $50 from $60, while maintaining a Hold rating due to reduced revenue estimates in future years of its DCF model. Despite beating Q2 2026 estimates and increasing 2026 revenue guidance, Veracyte's stock dropped …

Veracyte (VCYT) Stock Sinks As Profit Strength Meets Reimbursement Doubt

VERACYTE, INC. 2026: Revenue $150.32M, EPS $0.31— 10-Q Summary

Veracyte (VCYT) reported its second-quarter 2026 results, showing significant growth with revenue reaching $150.32M and diluted EPS of $0.31. This represents a 15.5% year-over-year increase in revenue and a substantial turnaround from a net loss in the previous year, driven by strong testing revenue …

Needham raises Veracyte stock price target to $69 on strong Q2 beat

Needham has increased its price target for Veracyte (NASDAQ:VCYT) shares to $69 from $57, maintaining a Buy rating, following the company's strong second-quarter results where revenue and EPS surpassed consensus estimates. Veracyte also raised its 2026 revenue guidance and is noted for its financial …

Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Veracyte (VCYT) is back in focus after raising its 2026 revenue guidance to a range of US$590 million to US$596 million, and releasing detailed second …

Veracyte, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:VCYT) 2026-07-31

Veracyte, Inc. (VCYT) published a slide deck for its 2026 Q2 earnings call, reporting earnings per share (EPS) of $0.54, which beat estimates by $0.11. The company's revenue reached $150.32 million, surpassing expectations by $5.84 million and representing a 15.49% year-over-year increase. This presentation …

Veracyte (NASDAQ:VCYT) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Freedom Capital raises Veracyte stock price target on strong earnings

Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) reported strong Q2 results, with earnings of $0.54 per share and revenues of $150.32 million, both surpassing Zacks Consensus Estimates. The company has consistently exceeded EPS and revenue expectations over the past four quarters, and its stock has significantly outperformed the S&P …

Veracyte Inc (VCYT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Launches ...

This article first appeared on GuruFocus. Total Revenue: $150.3 million in Q2 2026, up 15% year-over-year. Testing Revenue: $145.7 million, up 19% year-over-year. Total Volume: Approximately 51,000 tests, up 13% year-over-year. Testing Volume: 48,389 tests, up 14% year-over-year. Testing ASP: $3,010, up 4% year-over-year; …

Transcript : Veracyte, Inc., Q2 2026 Earnings Call, Jul 30, 2026

This article is a transcript of Veracyte, Inc.'s Q2 2026 Earnings Call held on July 30, 2026. The company reported increased Q2 non-GAAP earnings and revenue, leading to a raised revenue guidance for the full year 2026. The transcript includes opening remarks and indicates …

Veracyte posts 15% revenue surge in Q2, raises FY26 guidance

Veracyte Inc. reported a strong Q2 2026 with a 15% revenue increase, reaching $150.3 million, and a significant turnaround to a GAAP net income of $25.5 million. Driven by robust demand for its cancer diagnostics portfolio, particularly Decipher Prostate and Afirma tests, the company …

Veracyte Releases Q2 2026 Financial Results

Veracyte (NASDAQ: VCYT) reported strong Q2 2026 financial results, with non-GAAP EPS of $0.54, surpassing estimates, and revenue of $150.3M, exceeding expectations by 4.0%. The company's Decipher Prostate test was a key growth driver, and full-year revenue guidance is set at $590.0M to $596.0M. …

Veracyte Q2 revenue rises 15% to $150.3 million

Earnings Flash (VCYT) Veracyte, Inc. Posts Q2 Adjusted EPS $0.54 per Share, Vs. FactSet Est of $0.43

Veracyte, Inc. (VCYT) reported its Q2 adjusted EPS of $0.54 per share, significantly surpassing the FactSet estimate of $0.43 per share. This financial update highlights the company's strong performance during the second quarter.

Veracyte: Q2 Earnings Snapshot

Veracyte Inc. (VCYT) reported robust second-quarter results, with profits reaching $25.5 million, or 31 cents per share. After adjustments, earnings were 54 cents per share, surpassing Wall Street's expectation of 43 cents. The molecular diagnostic company also exceeded revenue forecasts, posting $150.3 million against …

Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat

Veracyte, Inc. (VCYT) saw its shares advance significantly during Q2 2026 due to a strong earnings beat and raised full-year guidance, driven by double-digit volume growth in its Decipher test and improved Afirma performance. Meridian Small Cap Growth Fund highlighted VCYT as a key …

VCYT|Veracyte Inc|Price:55.730|Chg%:+0.080

This article provides a comprehensive analysis of Veracyte Inc (VCYT), highlighting its strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It details the company's diagnostic products for various cancers, institutional ownership, and analyst ratings, indicating a positive …